Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Antibody responses to BNT162b2 mRNA COVID-19 vaccine in previously infected Thai children aged 5–11 years
TCTR20230123005Phase 4Completed
- Sponsor
- National Vaccine Institute
- Start
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of tozinameran in coronavirus disease 2019 (COVID-19), sponsored by National Vaccine Institute. Started Mar 2022; status: completed.
02
Drugs
tozinameran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on TCTR20230123005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20230123005.